Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab Conditioning for HLA-Mismatched Stem Cell Transplant
NCT00040846Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2001
- Primary completion
- Dec 2009
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of alemtuzumab in hematologic malignancy, sponsored by Fred Hutchinson Cancer Center. Started Nov 2001; status: completed.
02
Drugs
alemtuzumab
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00040846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040846.